

2018

英文論文

1. 2018 Kamata K, Takenaka M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, **Kudo M**: Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. **Gastrointest Endosc**, 87:158-163, 2018 (IF=7.204).
2. 2018 **Kudo M**, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. **Lancet Gastroenterol Hepatol** 3:37-46, 2018 (IF=0.000).
3. 2018 Nishiyama H, Nagai T, **Kudo M**, Okazaki Y, Azuma Y, Watanabe T, Goto S, Ogata H, Sakurai T: Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. **Biochem Biophys Res Commun** 459:273-279, 2018 (IF=2.466).
4. 2018 Minaga K, Takenaka M, Omoto S, Miyata T, Kamata K, Yamao K, Imai H, Watanabe T, Kitano M, **Kudo M**: A case of successful transluminal drainage of walled-off necrosis under contrast-enhanced harmonic endoscopic ultrasonography guidance. **J Med Ultrason** 45:161-165, 2018 (IF=0.455).
5. 2018 Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Kashida H, Chikugo T, Chiba Y, Nakai T, Takeyama Y, Lisotti A, Fusaroli P, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions. **Dig Endosc** 30:98-106, 2018 (IF=3.238).
6. 2018 Takayasu K, Arie S, Sakamoto M, Matsuyama Y, **Kudo M**, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan: Impact of resection and ablation for single hypovascular hepatocellular

carcinoma ≤ 2 cm analysed with propensity score weighting. **Liver Int** 38:484-493, 2018 (IF=4.500).

7. 2018 **Kudo M**: Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. **Liver Cancer** 7:1-19, 2018 (IF=7.854).
8. 2018 **Kudo M**: Combination cancer immunotherapy in hepatocellular carcinoma. **Liver Cancer** 7:20-27, 2018 (IF=7.854).
9. 2018 **Kudo M**, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. **Lancet** 391:1163-1173, 2018 (IF=53.254).
10. 2018 Matsui S, Kashida H, **Kudo M**: Gastric inverted hyperplastic polyp mimicking a papilla. **Am J Gastroenterol** 113:462, 2018 (IF=10.231).
11. 2018 Ikeda M, **Kudo M**, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE Study Group: Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. **J Gastroenterol** 53:281-290, 2018 (IF=5.561).
12. 2018 Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, **Kudo M**: Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. **Eur Radio** 28:1986-1993, 2018 (IF=4.027).
13. 2018 Minaga K, Takenaka M, Kamata K, **Kudo M**: Transrectal endoscopic

ultrasound-guided paracentesis for diagnosis of malignant ascites in the pelvis. **Dig Liver Dis** 50:311, 2018 (IF=3.287).

14. 2018 Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, **Kudo M**: Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease. **J Crohns Colitis** 12:499-502, 2018 (IF=6.637).
15. 2018 **Kudo M**, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S: Regional differences in efficacy, safety and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study. **Liver Cancer**, 7:148-164, 2018 (IF=7.854).
16. 2018 **Kudo M**, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. **Lancet Gastroenterol Hepatol** 3:424-432, 2018 (IF=0.000).
17. 2018 Minaga K, Watanabe T, Kamata K, Asano N, **Kudo M**: Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review. **World J Gastroenterol** 24:1725-1733, 2018 (IF=3.300).
18. 2018 Raoul JL, **Kudo M**, Finn RS, Edeline J, Reig M, Galle PR: Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. **Cancer Treat Rev** 68:16-24, 2018 (IF=8.122).
19. 2018 **Kudo M**: Cabozantinib as a second-line agent in advanced

hepatocellular carcinoma. **Liver Cancer** 7:123-133, 2018 (IF=7.854).

20. 2018 **Kudo M**: Management of hepatocellular carcinoma in Japan as a world-leading model. **Liver Cancer** 7:134-147, 2018 (IF=7.854).
21. 2018 Matsui S, Kashida H, **Kudo M**: Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices. **Ann Gastroenterol** 31:636, 2018 (IF=0.000).
22. 2018 Minaga K, Takenaka M, Okamoto A, Omoto S, Miyata T, Imai H, **Kudo M**: Reintervention for stent occlusion after endoscopic ultrasound-guided hepaticogastrostomy with novel use of a precut needle-knife. **Endoscopy** 50: E153-154, 2018 (IF=6.629).
23. 2018 Minaga K, Takenaka M, Kamata K, Yoshikawa T, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakamoto H, Kitano M, **Kudo M**: Alleviating pancreatic cancer-associated pain using endoscopic ultrasound-guided neurolysis. **Cancers (Basel)** 10:E50, 2018 (IF=5.326).
24. 2018 Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, **Kudo M**, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX: Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. **Brit J Cancer** 119:19-26, 2018 (IF=5.922).
25. 2018 Yen CJ, Muro K, Kim TW, **Kudo M**, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC: Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials. **J Glob Oncol**:1-12, 2018 (IF=0.000).

26. 2018 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, **Kudo M**, for the KEYNOTE-224 investigators: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. **Lancet Oncol** 19:940-952, 2018 (IF=36.418).
27. 2018 Okamoto K, Watanabe T, Komeda Y, Okamoto A, Minaga K, Kamata K, Yamao K, Takenaka M, Hagiwara S, Sakurai T, Tanaka T, Sakamoto H, Fujimoto K, Nishida N, **Kudo M**: Dysbiosis-associated polyposis of the colon-cap polyposis. **Front Immunol** 9:918, 2018 (IF=5.511).
28. 2018 Nishida N, **Kudo M**: Immune checkpoint blockade for the treatment of human hepatocellular. **Hepatol Res** 48:622-634, 2018 (IF=3.415).
29. 2018 Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, **Kudo M**, Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S: How to perform contrast-enhanced ultrasound (CEUS). **Ultrasound Int Open** 4:E2-15, 2018 (IF=0.000).
30. 2018 Yamao K, Kitano M, Takenaka M, Minaga K, Sakurai T, Watanabe T, Kayahara T, Yoshikawa T, Yamashita Y, Asada M, Okabe Y, Hanada K, Chiba Y, **Kudo M**: Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in west Japan. **Gastrointest Endosc** 88:66-75, 2018 (IF=7.204).

31. 2018 Takenaka M, Arisaka Y, Sakai A, Kobayashi T, Shiomi H, Masuda A, **Kudo M**: A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (Uneven method). **Endoscopy** 50:E229-230, 2018 (IF=6.629).
32. 2018 Takenaka M, Yamao K, **Kudo M**: Novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double lumen cannula (Uneven method). **Dig Endosc** 30:808-809, 2018 (IF=3.238).
33. 2018 Yoshida A, Hagiwara S, Watanabe T, Nishida N, Ida H, Sakurai T, Komeda Y, Yamao K, Takenaka M, Enoki E, Kimura M, Miyake M, Kawada A, **Kudo M**: Erythropoietic Protoporphyrin-related Hepatopathy Successfully Treated with Phlebotomy. **Intern Med** 57:2505-2509, 2018 (IF=0.817).
34. 2018 Watanabe T, Minaga K, Kamata K, **Kudo M**, Strober W: Mechanistic insights into autoimmune pancreatitis and IgG4-related disease. **Trends Immunol** 39:874-889, 2018 (IF=14.188).
35. 2018 **Kudo M**: Proposal of primary endpoints for TACE combination trials with systemic therapy: Lessons learned from 5 negative trials and the positive TACTICS trial. **Liver Cancer** 7:225-234, 2018 (IF=7.854).
36. 2018 **Kudo M**: Extremely high objective response rate of Lenvatinib: Its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma. **Liver Cancer** 7:215-224, 2018 (IF=7.854).

37. 2018 Takenaka M, Minaga K, **Kudo M**: Cannulation method for intra-diverticular papilla with long oral protrusion using biopsy forceps for axis alignment. **Dig Endosc** 30:700-701, 2018 (IF=3.238).
38. 2018 Kamata K, Takenaka M, Minaga K, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, **Kudo M**: Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. **Endosc Ultrasound** 7:349-350, 2018 (IF=3.323).
39. 2018 Tanaka H, Kamata K, Takenaka M, **Kudo M**: Contrast-enhanced harmonic EUS image of pancreatic mucinous cystadenocarcinoma. **Internal Med** 57:3051-3052, 2018 (IF=0.817).
40. 2018 Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, **Kudo M**, Hiasa Y, Izumi N: Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. **Hepatol Res** 48:821-828, 2018 (IF=3.415).
41. 2018 Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Nakai A, Tanaka H, Chiba Y, Watanabe T, Sakurai T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, Kitano M, **Kudo M**: Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. **Digest Endosc** 30:659-666, 2018 (IF=3.238).
42. 2018 Minaga K, Kitano M, Itonaga M, Imai H, Miyata T, Yamao K, Tamura T, Nuta J, Warigaya K, **Kudo M**: Endoscopic ultrasound-guided biliary drainage using a newly designed metal stent with a thin delivery system: A preclinical study in phantom and porcine models. **J Med Ultrason** 45:391-397, 2018 (IF=0.455).

43. 2018 **Kudo M**: Ramucirumab as second-line systemic therapy in hepatocellular carcinoma. **Liver Cancer** 7:305-311, 2018 (IF=7.854).
44. 2018 **Kudo M**: Systemic therapy for hepatocellular carcinoma: Latest advances. **Cancers** 10:E412, 2018 (IF=5.326).
45. 2018 Kamata K, Watanabe T, Minaga K, Strober W, **Kudo M**: Autoimmune pancreatitis mouse model. **Curr Protoc Immunol**, 2018 (doi: 10.1002/cpim.41) (IF=0.000).
46. 2018 Otsuka Y, Kamata K, Minaga K, Takenaka M, Watanabe T, **Kudo M**: Acute pancreatitis with disturbed consciousness caused by hyperparathyroidism. **Internal Med** 57:3075-3078, 2018 (IF=0.817).
47. 2018 Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, García-Fiñana M, **Kudo M**, Kumada T, Roayaie S, Johnson PJ: Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. **J Hepatol** 69:1284-1293, 2018 (IF=15.040).
48. 2018 Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, **Kudo M**: Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B. **Antivir Ther** 23:513-521, 2018 (IF=2.594).
49. 2018 Sofue K, Tsurusaki M, Mileto A, Hyodo T, Sasaki K, Nishii T, Chikugo T, Yada N, **Kudo M**, Sugimura K, Murakami T: Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data. **Hepatol Res**

48:1008-1019, 2018 (IF=3.415).

50. 2018 Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, **Kudo M**, Nakagawa K: Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer. **J Thorac Oncol** 13:e239-e241, 2018 (IF=10.336).
51. 2018 Yoshida A, Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Matsumoto I, Takeyama Y, Chikugo T, **Kudo M**: Neurilemmoma mimicking a multilocular cystic lesion of the liver. **Intern Med** 57:3377-3380, 2018 (IF=0.817).
52. 2018 Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, **Kudo M**, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX: Corrigendum to "Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study". **Eur J Cancer** 100:135-136, 2018 (IF=7.191).
53. 2018 Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, **Kudo M**, Barr RG: Liver ultrasound elastography: An update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations. **Ultrasound Med Biol** 44:2419-2440, 2018 (IF=2.645).
54. 2018 Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, **Kudo M**: Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian

patients. **Invest New Drugs** 36:1072-1084, 2018 (IF=3.484).

55. 2018 Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, **Kudo** **M**: Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy. **Cancers** 10: E367, 2018 (doi: 10.3390/cancers10100367) (IF=5.326).